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A B S T R A C T
Purpose: To review our cohort of patients with Dravet syndrome and determine if patients with SCN1A
mutations can also express mitochondrial disease due to electron transport chain dysfunction.
Methods: A retrospective chart review was used to describe clinical manifestations and retrieve
biochemical testing, neuroimaging, gene sequencing, and electroencephalographic results of patients
expressing both mitochondrial disease and Dravet syndrome.
Results: Two children were found to have pathological mutations in the SCN1A gene and defects in
mitochondrial electron transport chain complex activity. Both developed early febrile and medically
intractable afebrile seizures with resulting neurocognitive decline. In the ﬁrst patient, a muscle biopsy
demonstrated complex IV dysfunction and in the second patient, complex III dysfunction. Patient 1 had
more difﬁcult to control seizures, and had features consistent with severe autism. Patient 2, who had
earlier control and less severe seizures, did not have features of autism. Patient 1 had SCN1A missense
mutation, c. 3734 G > A and patient 2 had a mutation, c. 3733 C > T, which produces a truncation
mutation.
Conclusion: Our two patients underscore the need to rule out possible co-morbid mitochondrial disease
and Dravet syndrome. The treatment of seizures for each is different, with valproic acid being ﬁrst line
treatment in Dravet syndrome and contraindicated in many mitochondrial diseases, due to possible
induction of liver failure and death. Failure to pursue complete diagnostic evaluation might inﬂuence
medication choice, possible seizure control, and developmental outcomes.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.1. Introduction
Dravet syndrome, a catastrophic epilepsy syndrome, is associ-
ated with mutations in the SCN1A gene in up to 90% of cases.1,2
Development in the ﬁrst year of life is typically normal, but early
febrile and subsequent afebrile intractable seizures lead to
developmental regression, ataxia, and autistic-like behaviors.3,4
Mitochondrial disease can present similarly.5–8 Recently, a single
patient was reported to have mutations in the mitochondrial DNA
replicase and repair enzyme, polymerase gamma 1 (POLG) and
pathological mutation in SCN1A, but with normal mitochondrial
electron transport chain activities.9 This case demonstrated that
both mitochondrial disease and Dravet syndrome may co-exist.
We present two children with co-morbid SCN1A mutations and
deﬁnite mitochondrial disease10 due to electron transport chain* Corresponding author. Tel.: +1 206 987 2078; fax: +1 206 987 2649.
E-mail address: russ.saneto@seattlechildrens.org (R.P. Saneto).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.08.010deﬁciencies, and highlight the similar clinical manifestations,
including autistic features of both these diseases.
2. Methods
We reviewed our cohort of 24 patients with pathological
mutations in the SCN1A gene for possible mitochondrial disease.
This study was approved by our Institutional Review Board.
Childhood Autism Rating Scale [CARS11] assessment was per-
formed using clinical observation, chart review and parental
interview. The CARS consists of 14 domains assessing behaviors
associatedwith autism. Total scores can range from a low of 15 to a
high of 60; scores below 30 indicate that an individual is in the
non-autistic range, scores between 30 and 36.5 indicate mild to
moderate autism and scores from 37 to 60 indicate severe
autism.12 CARS testing was carried out by one of the authors
(A.K.C.). SCN1A sequencing was performed commercially (Athena
Diagnostics, MA). Electron transport chain enzyme activities were
obtained from ﬂash frozen, 808, vastus lateralis muscle biopsyvier Ltd. All rights reserved.
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of Energy Metabolism (CIDEM), Cleveland, OH).
3. Results
3.1. Patient 1
Patient 1 is now 15-years old. He initially presented with 2
febrile seizures and subsequent afebrile seizures around 9 months
of age. His seizures became intractable and he was admitted 9
times for tonic clonic status epilepticus, with the last status
epilepticus event occurring around age 4 years. His status
epilepticus events had duration of up to 2.5 h. He required
insertion of a gastrointestinal-tube for nutrition due to failure to
gain weight. He developed an intention tremor at age 3 years and
has had severe constipation his whole life. His seizures have
evolved into staring ‘‘spells’’ and drop seizures. Serial electro-
encephalograms (EEG) were notable for background slowing and
bilateral independent temporal onset of seizures captured by
Video-EEG monitoring. Brain magnetic resonance imaging (MRI)
scans performed at age 2, 4, and 8 years were interpreted as
without abnormality. Until seizure onset, early development was
normal. He was initially treated with phenobarbital, and subse-
quentlywith carbamazepine, lamotrigine, clonazepam, topiramate
and zonisamide without seizure control. A vagus nerve stimulator
was implanted at age 7-1/2 years without change in seizure
frequency. Currently, he is having 1 short, complex partial seizure
every two weeks while on the combination of valproic acid,
zonisamide, and lamotrigine. He was started on valproic acid
before muscle biopsy results returned several years ago.
The family history was signiﬁcant for epilepsy. The patient’s
father had a seizure disorder since 9 years of age, which was stable
on phenytoin. He has been diagnosed with schizophrenia. Epilepsy
is present in 2 paternal half-sisters and not in a full biological
brother. The mother had no mutations in the SCN1A gene. Father
did not consent for gene testing.
A metabolic work-up included normal urine organic acids,
lactate and pyruvate, and plasma amino acids. A comparative
genomic hybridization (CGH) array study demonstrated an
interstitial deletion at 3p26.2 (also present in normal mother).
Due to unexplained seizures and encephalopathy, muscle biopsy
was performed and demonstrated no histochemical or electron
microscopy abnormalities. Enzymatic activity showed evidence of
complex IV defect (Table 1). On gene sequencing a pathological
SCN1Amutation, c.3734G > A,was found that produces amissense
mutation (domain 3, transmembrane region 2, external loop).13,14
Developmentally, he is now profoundly delayed with severe
autistic behaviors. He has no expressive language and frequent
self-injurious behavior treated by atypical antipsychotic drugs. On
the CARS examination his score was 41, which is in the severely
autistic range.
3.2. Patient 2
Patient 2 is now 6-years old. He developed febrile seizures at
age 6months and progressed to atypical absence seizures, complex
partial seizures and frequent generalized tonic clonic seizures.Table 1
Electron transport chain complex activity.a
Patient Complex I Complex I/III Complex II
29.912.9 1.21.1 0.80.4
1 28.5 (95%) 0.5 (40%) 1.3 (157%)
2 17.9 (60%) 0.4 (31%) 0.7 (90%)
a Activity: mmol/min/g wet weight.Between ages 2–3 years, he had frequent episodes of tonic clonic
status epilepticus lasting up to 1 h. An EEG at 12 months
demonstrated generalized slow spike and wave complexes of 2–
3 Hz. Clinically, he has a wide base gait with ataxia. There is a mild
axial hypotonia present. MRI of the brain at age 1 year was normal.
Until the seizures began, early development was normal. The
family history was unremarkable. Initially, he was treated with
phenobarbital, and subsequently with levetiracetam, topiramate,
lamotrigine, carbamazepine, and ethosuximide without seizure
control. At age 3 years, he was started on the ketogenic diet and
had marked improvement in seizure control. Clobazam was then
added resulting in further improvement, but not seizure freedom.
He is currently having approximately 1 short atypical absence
seizure every 2 weeks.
Metabolicwork-up includednormal urine organic acids, cerebral
spinal ﬂuid studies, and serum acylcarnitine proﬁle. Plasma amino
acid proﬁle demonstrated elevation in alanine. Two venous lactate
determinationswere elevated (3.6, 3.0, normal<2.1 mM). Sequenc-
ing of SCN1A revealed a pathological mutation, c.3733 C> T, which
changes arginine to a stop codon in domain 3, transmembrane
region, external loop.13,14 POLG, POLG2, and C10orf2 sequencing
were negative. Due to encephalopathy, abnormal biochemistries
and seizures, a muscle biopsy was performed and found signiﬁcant
for a complex III defect (Table 1). There were no muscle
abnormalities on histochemical or electron microscopy.
Patient 2 nowhasmild dysarthric speech,mildmotor delay, and
mild ataxia. He made signiﬁcant progress in language acquisition
after starting the ketogenic diet. His score on the CARS assessment
was 25.5, which is not in the autistic range.
4. Discussion
Dravet syndrome is associated with SCN1A genemutations in up
to 90% of cases.1,2,15,16 Mutations within SCN1A induce phenotypes
ranging from benign febrile seizures to catastrophic epilepsy.3
Seizure onset is in the ﬁrst year of life and typically evolves into
medically intractable seizures, with resultant neurocognitive
regression and development of autistic behaviors.16 Logically, one
would correlate the degree of intellectual disability with seizure
severity and frequency.17 Both patients possess pathologic SCN1A
mutations13,14 and demonstrated the typical course of early febrile
seizures progressing to medically refractory epilepsy with develop-
mental regression. The development of patient 2was less impacted,
debatably in part, due to earlier control of status events (age 3 years
versus 4 years). Patient 2 also had shorter duration of individual
status events (less than 1 h versus 2.5 h). The earlier seizure control,
shorter duration of status events, and younger age of improved
seizure control arguably lead to improved overall developmental
outcome, as evidence by his CARS score, which is not in the autistic
range. Neither of our patients had prolonged atypical absence
seizures,which have been associatedwith increased developmental
involvement.18 Age of seizure control and type of uncontrolled
seizures may be a mechanism of milder cognitive impairment, but
this needs to be clariﬁed in larger studies.
Due to clinical presentation of possible mitochondrial disease,
both patients were tested for mitochondrial disease by muscle
biopsy. Patient 1 was tested due to progressive encephalopathyComplex III Complex IV Citrate synthase
15.26.8 148.967.2 18.64.7
8.5 (55%) 30.9 (21%) 27.4 (142%)
2.5 (16%) 70.2 (47%) 20.0 (107%)
Table 2
Clinical summary.
Patient 1 Patient 2
Gender and age of
seizure onset
Male/9months Male/6months
Development prior
to seizure onset
Normal Normal
Clinic symptoms FFT, tremor,
encephalopathy
Ataxia, hypotonia
Constipation Encephalopathy
Autistic behavior Developmental delay
Seizure types Atypical absence,
drops
Atypical absence
CPS Tonic, CPS
Abnormal lab testing None Elevation Lac and Ala
Neuroimaging Normal Normal
ETC abnormality/CS
(normalized 100%)a
Complex IV (15%) Complex III (15%)
SCN1A mutation c. 3734 G>A c. 3733 C>T
FFT: failure to thrive; Lac: lactate; Ala: alanine; CPS: complex partial seizure; ETC:
electron transport chain; CS: citrate synthase.
Both patients meet the criteria of deﬁnite mitochondrial disease.10 Patient 1 has
deﬁnite mitochondrial disease due to multiple (3 or more) system involvement
(major) and <20% ETC activity (major) and Patient 2 has deﬁnite mitochondrial
disease due to <20% ETC activity (major), metabolic indicators of ETC abnormality
(minor) and systems compatible with ETC abnormality (minor).
a Activity of ETC complex is normalized to a mean control activity of marker
enzyme activity of 100%, the residual activity is presented as percent of normal.
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dysfunction (Table 1). Patient 2 was tested for mitochondrial
disease due to the presence of encephalopathy, hypotonia and
biochemical abnormalities, and was found to have complex III
dysfunction (Table 1). Both patients meet criteria for deﬁnite
mitochondrial disease (Table 2).10 As with our patients, the clinical
presentation of mitochondrial diseases and Dravet syndrome can
present similarly. Both disorders can present with normal early
development followed by onset of medically refractory seizures
with frequent episodes of status epilepticus, and associated
developmental regression.6,8,19 Frank autistic behaviors can be
seen in patients with electron transport chain defects.20 Our
patients demonstrate the clinical similarity between the two
disorders and underscore the expanding etiologies of co-morbid
Dravet syndrome and mitochondrial disease.
The etiology of the co-morbidity is not entirely obvious. The
etiology is clear in the patient with digenic mutations in POLG and
SCN1A genes.9 Mutations in POLG were not found in patient 2.
Clinically,mutations in POLG giving rise to Alpers syndrome are not
likely in patient 1 as he has been on long-term valproic acid
without liver problems.19,21,22 In addition, the lack of progressive
neurocognitive decline is also suggestive that he does not have
Alpers syndrome.5 Therefore, co-morbid digenetic mutations in
POLG and SCN1A do not explain our two patients. Our ﬁndings
indicate that there are multiple etiologies for this co-morbidity,
frank genetic mutations in genes causing known mitochondrial
disease, i.e. POLG, and defects in the electron transport chain. The
genetic components of the latter remain only partially known.
The possibility of a single mechanism for Dravet and
mitochondrial diseases of our patients is not clear. As far as we
understand, muscle does not express SCN1A. There is a report of a
transactivating factor, ERRg regulating expression of SCN1A and
multiple mitochondrial genes in animal cardiac muscle.23 Howev-
er, it is not clear if co-regulation occurs in human tissues such as
brain and skeletal muscle. Findings in our two patients would
suggest that there are likely multiple mechanisms for diverse
phenotypes in some patients with Dravet syndrome. Both of our
patients had alterations within the SCN1A gene encoding the same
amino acid, Arg1245. One patient had amissensemutation and the
other a truncation mutation. The latter patient would logicallyhave the more severe phenotype, however his disease was much
milder. This ﬁnding would argue that there are other mechanisms
inﬂuencing the SCN1A phenotype. Given the previous digenic
mutations in POLG and SCN1A in one patient, we think it is
reasonable to assume that multiple gene mutations could be
altering phenotype in some patients. The ﬁnding of co-morbidity of
SCN1A mutations and mitochondrial defects would substantiate
this suggestion.
The ﬁndings of our 2 patients and the patient reported by
Bolszak et al.9 pose a seizure treatment dilemma. Valproic acid
dosing is a ﬁrst line therapy in Dravet patients.24 However, valproic
acid can induce liver failure if mutations in POLG are found.19,25,26
Unfortunately, there are no pathogenomic clinical ﬁndings of
either Dravet syndrome or Alpers syndrome to clarify when POLG
sequencing should occur. There are some clinical clues based on
EEG, biochemical, and neuroimaging ﬁndings that may help the
clinician select those patients who need further workup, i.e. POLG
sequencing or other mitochondrial diseases.19,27–29 The use of
valproic acid in other types of mitochondrial diseases related to
electron transport chain deﬁciencies has demonstrated signiﬁcant
side effects and its use has been questioned.30 Our patients suggest
that co-morbid Dravet syndrome and electron transport chain
deﬁciencies are not uncommon. Diagnosis of possible mitochon-
drial disease and the use of valproic likely represent a concern
outside isolated digenic POLG and SCN1A mutations.
Epileptic and metabolic-induced encephalopathies are not
uncommon. We report two patients who have two distinct
mechanisms for progressive encephalopathies. Both have Dravet
syndrome and mitochondrial disease. Our patients demonstrate
the range of clinical ﬁndings that can be seen in either disease,
intractable seizures, developmental delay, autism, ataxia, progres-
sive neurocognitive involvement and add to the dilemma of
phenotype:genotype for each disease. How the two disorders
complement each other giving rise to disease involvement remains
unknown. Much larger populations of patients with co-morbid
disease are needed to tease out how each diseasemay complement
one another in disease manifestations. The awareness of the
clinician deciding when to do multiple testing is paramount to
prevent medication-induced morbidity/mortality, as well as
proper intervention to control seizures. Given select clinical and
biochemical ﬁndings, muscle biopsy and/or sequencing of both
POLG and SCN1A should be undertaken.
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